Regulatory reform welcome, but multiple challenges still remain to ensure a prosperous UK Life Sciences environment

Media centre

Commenting on the regulatory reforms announced in today’s Budget, Grace Mitchell, Market Access Specialist in LCP’s Health Analytics team, said:

“We welcome the news of reforms to the regulatory process for medicines in the UK, as announced in the Chancellor’s spring statement. The streamlining of the MHRA’s regulatory process through the exploration of relationships with trusted regulators in the US, Europe, and Japan should accelerate patient access to high impact medicines and technologies, thereby improving health outcomes and promoting a healthier, more economically active population. We note, however, that multiple challenges remain to ensure  a prosperous Life Sciences environment in the UK. It is imperative that novel medicines are successfully integrated into the patient care pathway within the NHS to enable sufficient and equitable access for all patients. Similarly, the recent decline in investment in UK R&D and fall in recruitment of patients to clinical trials must be addressed to promote the UK as a thriving environment for investors, and achieve the UK Life Sciences Vision.”